Tag: acute myeloid leukemia

Two FDA-approved antibody-drug conjugates (ADCs)—gemtuzumab ozogamicin (Mylotarg®; Pfizer/Wyeth) and belantamab mafodotin (Blenrep®; GSK)—were withdrawn from the U.S. market after confirmatory trials failed to verify...

A promising avenue is the targeting of CD37, a tetraspanin family member broadly expressed on malignant myeloid blasts but with limited expression on normal hematopoietic stem cells. Debio 1562M,** a second-generation novel antibody-drug conjugate (ADC) developed by Debiopharm, is designed to target CD37 and deliver a potent cytotoxic payload directly to tumor cells. Here, we review the preclinical development, mechanism of action, and therapeutic potential of Debio 1562M in AML and MDS.

Acute Myeloid Leukemia (AML) is a heterogeneous and highly aggressive hematologic malignancy characterized by a wide range of cytogenetic and molecular abnormalities that define distinct disease subgroups.

During the annual meeting for the American Association for Cancer Research (AACR) meeting held April 25 - 30, 2025 in Chicago, Illinois, Swiss-based Debiopharm presented comprehensive preclinical results for Debio 1562M (see ADC Drugmap) a next-generation Antibody-Drug Conjugate (ADC) targeting the cell surface glycoprotein CD37 being developed to be a potential first in class therapy in Acute Myeloid Leukemia (AML) and Myelodysplastic syndrome (MDS).

The U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for BL-M11D1, an antibody-drug conjugate (ADC) binding CD33, a sialic acid-dependent cytoadhesion molecule and a member of the sialic acid-binding immunoglobulin (Ig)-like lectins (Siglecs), which is a subset of the immunoglobulin superfamily molecules.

Updated data from the ongoing Phase 1b study of luveltamab tazevibulin (luvelta; STRO-002; Sutro BioPharma) in combination with bevacizumab (Avastin®; Genentech/Roche) for patients with...

Results from a preclinical toxicity evaluation study with BVX001, a novel antibody-drug conjugates (ADC) being developed by BiVictriX, showed positive in vivo data when compared to gemtuzumab ozogamicin (Mylotarg™; Pfizer).

Initial safety and efficacy findings from an open-label, dose-escalation and expansion cohorts of the Phase 1b/2 study of pivekimab sunirine (IMGN632), a CD123 (Interleukin-3 alpha...

Gilead Sciences snf ImmunoGen have agreed to jointly evaluate the safety and anti-leukemia activity of pivekimab sunirine (IMGN632), a CD123 (Interleukin-3 alpha chain/IL-3 Rα) -targeting...

Actinium Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that its intellectual property portfolio around its lead Phase 3 candidate, I-131 apamistamab (Iomab-B), has been further...